POST Samsung Medical Center Effect of Postconditioning on Myocardial Reperfusion during Primary Percutaneous Coronary Intervention Joo-Yong Hahn / Hyeon-Cheol.

Slides:



Advertisements
Similar presentations
Post-conditioning the human heart to reduce infarct size
Advertisements

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
A Safety and Efficacy Study of Integrilin Facilitated PCI versus Primary PCI in ST Elevation Myocardial Infarction Principal Investigator: Michel Le May,
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
Enhancement of thrombolysis in AMI is an unmet clinical need Increase the rate of reperfusion without increasing bleeding Reduce the time to complete reperfusion.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Effect of Postconditioning on Myocardial Reperfusion during Primary Percutaneous Coronary Intervention Joo-Yong Hahn / Hyeon-Cheol Gwon On behalf of the.
A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park, MD, PhD, University.
Presentation at a Non PCI Facility Requiring Transfer Does NOT Worsen Long-term Prognosis in Patients With STEMI Undergoing Primary Angioplasty. The HORIZONS-AMI.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
Samsung Medical Center Cardiac & Vascular Center Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Myung-Ho Jeong, Hyo-Soo Kim,
Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 A Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
Disclosure Statement of Financial Interest
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Strategies to Improve Inadequate Guide Catheter Support John S Douglas Jr MD S Tanveer Rab MD Emory University School of Medicine Atlanta Georgia Sunday.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Post-Approval.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
David E. Kandzari, MD on behalf of the BIONICS investigators
Disclosures Runlin Gao has received a research grant
Updates From NOTION: The First All-Comer TAVR Trial
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
For the HORIZONS-AMI Investigators
Thomas Stiermaier, MD; Suzanne de Waha, MD;
A Randomized, Prospective, Intercontinental Evaluation of a Bioresorbable Polymer Sirolimus-eluting Stent: the CENTURY II Trial: an Update with 2 Years.
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
European Society of Cardiology 2003
The HORIZONS-AMI Trial
3-Year Clinical Outcomes From the RESOLUTE US Study
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

POST Samsung Medical Center Effect of Postconditioning on Myocardial Reperfusion during Primary Percutaneous Coronary Intervention Joo-Yong Hahn / Hyeon-Cheol Gwon On behalf of the POST Trial Investigators Samsung Medical Center, Sungkyunkwan University School of Medicine

POST Samsung Medical Center Disclosure Statement of Financial Interest  Grant/Research Support  Consulting Fees/Honoraria  Major Stock Shareholder/Equity  Royalty Income  Ownership/Founder  Intellectual Property Rights  Other Financial Benefit  Abbott Vascular Korea, Medtronic Korea, Boston Scientific Korea  AstraZeneca, Daiichi Sankyo, Sanofi-Aventis  None Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial RelationshipCompany

POST Samsung Medical Center  Repetitive reversible ischemia during early reperfusion after the prolonged ischemic insult  Comparable protective effects to preconditioning in animal studies  Zhao ZQ et al. Am J Physiol Heart Circ Physiol 2003 Ischemic Postconditioning

POST Samsung Medical Center  Postconditioning reduced enzymatic infarct size in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).  Staat P et al. Circulation 2005, the first report in human  Inconsistent results of studies using CE-MRI for infarct size  Lonborg J et al. Circ Cardiovasc Interv 2010  Thuny F et al. J Am Coll Cardiol 2012  Sorensson P et al. Heart 2010  Freixa X et al. Eur Heart J 2012  Tarantini G et al. Int J Cardiol 2012  No large scale trials Ischemic Postconditioning PostC is Protective! PostC is harmful!

POST Samsung Medical Center  To evaluate the safety and efficacy of ischemic postconditioning in patients with STEMI undergoing primary PCI. Objective of Study Hypothesis Ischemic postconditioning can improve myocardial reperfusion after primary PCI. Hypothesis Ischemic postconditioning can improve myocardial reperfusion after primary PCI.

POST Samsung Medical Center Trial Design A multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial Postconditioning with primary PCI (n=350) Conventional primary PCI (n=350) STEMI patients undergoing primary PCI Randomization after diagnostic coronary angiogram (n=700) ClinicalTrials.gov identifier: NCT Assessment of myocardial reperfusion Clinical follow-up ST-segment resolution Myocardial blush grade Web-based P:C = 1:1 Stratified by infarct-related artery

POST Samsung Medical Center  Patients with STEMI undergoing primary PCI  Inclusion criteria  ST-segment elevation more than 1 mm in 2 or more contiguous leads  The presence of chest pain for less than 12 hours after symptom onset  Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 or 1 in the infarct-related artery  Target lesion in a native coronary vessel with reference diameter of 2.25 to 4.25 mm. Eligible patients

POST Samsung Medical Center  Hemodynamic instability or cardiogenic shock  Left bundle branch block on electrocardiogram (ECG)  Left main lesion  Rescue PCI after thrombolysis or facilitated PCI  Non-cardiac co-morbid conditions with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)  Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study. Exclusion Criteria

POST Samsung Medical Center Study Protocol  Postconditioning  Four episodes of 1-minute balloon occlusion and 1- minute deflation*  Immediately (within 1 minute) after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving reflow)  Aspirin 300 mg and clopidogrel 600 mg  Thrombus aspiration, predilation before stenting, or use of glycoprotein IIb/IIIa inhibitors were left to the operators’ discretion. *Staat P et al. Circulation 2005;112: IschemiaReperfusion Conventional PCI Postconditioning Ballooning for 1 min X 4

POST Samsung Medical Center Endpoints  Primary End point  Complete ST-segment resolution (STR >70%) at 30 minutes after the procedure  Secondary End Points  TIMI flow grade after PCI  Myocardial blush grade  Major adverse cardiac events (MACE: a composite of death, reinfarction, severe heart failure*, or stent thrombosis†) at 30 days  Each component of MACE at 30 days  Target vessel revascularization at 30 days * Heart failure with documented arterial partial pressure of oxygen less than 60 mmHg or with pulmonary edema documented radiographically or requiring intubation, 100% oxygen, or insertion of a mechanical support device. †Definite or probable stent thrombosis by the ARC definition

POST Samsung Medical Center Primary Endpoint The rate of complete STR The rate of complete STR in the conventional PCI group: 50% The expected rate of complete STR in the postconditioning group: 62.5% (relative increase 25%) Type I error 0.05 Sampling ratio of postconditioning : conventional PCI = 1:1 Sample Size Calculation A target sample size of 700 subjects would provide 91.7% power.

POST Samsung Medical Center Study Organization Principal Investigators 17 study investigators DSMB Data Safety Monitoring Board Core Laboratory ECG and angiographic data analyses CEAC Clinical Event Adjudication Committee The sponsors were not involved with the protocol development or the study process, including site selection, management, and data collection and analysis. CTC-SMC Trial Coordinating Center Grant Support 1) The Korean Society of Interventional Cardiology 2) The Sungkyunkwan University Foundation for Corporate Collaboration 3) Medtronic Korea

POST Samsung Medical Center Participating Centers Samsung Medical Center Samsung Changwon Hospital Kyungpook National University Hospital Hanil General Hospital Konyang University Hospital Korea University Anam Hospital Gyeongsang National University Hospital Eulji University School of Medicine Kangbuk Samsung Hospital Chungbuk National University Hospital Sejong General Hospital Daegu Catholic University Hospital Chung-Ang University Hospital Boramae Medical Center Yeungnam University Hospital Dankook University Hospital Kyung Hee Medical Center 17 Hospitals in Republic of Korea

POST Samsung Medical Center 700 Underwent randomization 350 Were assigned to postconditioning 323 Underwent postconditioning per protocol 349 Underwent conventional primary PCI 341 Were included in analysis of STR 335 Were included in analysis of STR 27 Did not undergo postconditioning per protocol 1 underwent coronary artery bypass grafting surgery 3916 Patients were assessed 350 Had clinical follow-up 3216 Were not enrolled 478 Declined to participate 1053 Had TIMI flow grade of 2 or Had hemodynamic instability or cardiogenic shock 47 Had left main lesions 36 Underwent rescue PCI or facilitated PCI 94 Non-cardiac co-morbid conditions with life expectancy <1 year 401 Participated in other studies 695 Had other reasons 350 Were assigned to conventional PCI Between July 2009 and June 2012

POST Samsung Medical Center Baseline Clinical Characteristics Postconditioning (n=350) Conventional PCI (n=350) P Value Age ― yr 60± Male sex 276/350 (78.9%)261/350 (74.6%)0.18 Body mass index* 24.1± ± Diabetes mellitus 84/346 (24.3%)87/346 (25.1%)0.79 Hypertension 161/341 (46.4%)159/349 (45.6%)0.82 Dyslipidemia 139/345 (40.3%)159/349 (45.6%)0.16 Current smoking 184/349 (52.7%)182/348 (52.3%)0.91 Previous myocardial infarction 10/344 (2.9%)9/348 (2.6%)0.80 Previous revascularization 20/346 (5.8%)16/349 (4.6%)0.48 Cerebrovascular disease 10/346 (2.9%)16/348 (4.6%)0.24 Chronic renal failure 4/345 (1.2%)2/348 (0.6%)0.45 Ejection fraction (%)50·0 (10.9)50·2 (11.6)0.88

POST Samsung Medical Center Angiographic Findings Postconditioning (n=350) Conventional PCI (n=350) P Value Number of diseased vessels /350 (54.0%)165/350 (47.1%) 299/350 (28.3%)115/350 (32.9%) 362/350 (17.7%)70/350 (20.0%) Infarct-related artery0.90 Left anterior descending163/350 (46.6%)157/350 (44.9%) Left circumflex38/350 (10.9%)40/350 (11.4%) Right coronary artery149/350 (42.6%)153/350 (43.7%) TIMI flow before PCI /350 (93.7%)324/347 (93.4%) 18/350 (2.3%)7/347 (2.0%) 2/314/350 (4.0%)16/347 (4.6%) TIMI = thrombolysis in myocardial infarction.

POST Samsung Medical Center Procedural Findings Postconditioning (n=350) Conventional PCI (n=350) P Value Symptom onset-to-reperfusion time ― min196 ( )195 ( )0.91 Door-to-reperfusion time ― min54 (43-73)56 (44-74)0.14 Thrombus aspiration158/350 (45.1)178/350 (50.9)0.13 Direct stenting43/350 (12.3)51/350 (14.6)0.38 Obtaining method of reflow0.69 Wire passage36/350 (10.3%)45/349 (12.9%) Thrombus aspiration111/350 (31.7%)114/349 (32.7%) Predilation ballooning202/350 (57.7%)189/349 (54.2%) Direct stenting1/350 (0.3%)1/349 (0.3%) Use of glycoprotein IIb/IIIa inhibitor81/350 (23.1)80/350 (22.9)0.93 Stent implantation337/350 (96.3)342/350 (97.7)0.28 Drug-eluting stent291/337 (86.4)295/342 (86.3)0.97 Total stent length, mm28.2± ± Stent diameter, mm3.3±

POST Samsung Medical Center Complete ST-segment Resolution PostconditioningConventional PCIP Value ECG analysis341/350 (97.4%)335/350 (95.7%)0.21 Time to ECG ― min31 (29-38)31 (29-37)0.77 Mean percent STR51.2±52.7%48.4±58.8%0.52 PostCConv (%) 1˚ Endpoint <30% 30-70% >70% Absolute difference, -1.0%; 95% confidence interval, -8.4% to 6.4%; P=

POST Samsung Medical Center PostC Conventional PCI Difference (95% Confidence Interval)P value Age <6587/211 (41.2%)88/205 (42.9%)-1.7 (-11.1 to 7.7)0.73  65 51/130 (39.2%) 0.0 (-11.7 to 11.7)0.99 Sex Male105/269 (39.0%)98/249 (39.4%)-0.3 (-8.7 to 8.0)0.94 Female33/72 (45.8%)41/86 (47.7%)-1.8 (-17.0 to 13.5)0.82 Infarct-related artery LAD32/158 (20.3%)28/151 (18.5%)1.7 (-7.2 to 10.5)0.70 Non-LAD106/183 (57.9%)111/184 (60.3%)-2.4 (-12.3 to 7.6)0.64 Symptom onset-to-reperfusion time <3 hours71/154 (46.1%)75/153 (49.0%)-2.9 (-13.9 to 8.2)0.61  3 hours 67/187 (35.8%)64/181 (35.4%)0.5 (-9.3 to 10.2)0.93 Thrombus aspiration Yes60/154 (39.0%)67/170 (39.4%)-0.5 (-11.0 to 10.1)0.93 No78/187 (41.7%)72/165 (43.6%)-1.9 (-12.2 to 8.3)0.72 Direct stenting Yes17/41 (41.5%)19/45 (42.2%)-0.7 (-20.7 to 19.4)0.97 No121/300 (40.3$)120/290 (41.4%)-1.1 (-8.9 to 6.9)0.80 Glycoprotein IIb/IIIa inhibitors Yes35/79 (44.3%)36/78 (46.2%)-1.9 (-17.0 to 13.4)0.82 No103/262 (39.3%)103/257 (40.1%)-0.8 (-9.1 to 7.6) Postconditioning Better -205 Conventional PCI Better

POST Samsung Medical Center TIMI = thrombolysis in myocardial infarction. MBG = Myocardial blush grade. Angiographic Outcomes Postconditioning (n=350) Conventional PCI (n=350) P Value TIMI flow after PCI0.08 0/1 8/349 (2.3%)19/348 (5.5%) 2 20/349 (5.7%)23/348 (6.6%) 3 321/349 (92.0%)306/348 (87.9%) MBG after PCI0.20 0/160/349 (17.2%)78/348 (22.4%) 2108/349 (30.9%)106/348 (30.5%) 3181/349 (51.9) (47.1)

POST Samsung Medical Center Clinical Outcomes at 1-month Postconditioning (n=350) Conventional PCI (n=350) Relative risk (95% CI)*P Value Death13 (3.7%)10 (2.9%) 1.30 ( )0.53 Cardiac death10 (2.9%)9 (2.6%) 1.11 ( )0.82 Reinfarction2 (0.6%)1 (0.3%) 2.00 ( ) 0.99† Severe heart failure 2 (0.6%)5 (1.4%) 0.40 ( ) 0.29† Stent thrombosis7 (2.0%)6 (1.7%) 1.17 ( )0.78 Target-vessel revascularization 3 (0.9%) 1.00 ( ) 0.99† MACE‡15 (4.3%)13 (3.7%) 1.15 ( )0.70 * Relative risk is for the postconditioning group as compared with the conventional PCI group. † The P value was calculated with the use of Fisher’s exact test. ‡ Major adverse cardiac event was a composite of death, reinfarction, severe heart failure, or stent thrombosis.

POST Samsung Medical Center Resolution of ST-Segment Elevation (%) Myocardial Blush Grade Postprocedural TIMI flow grade 320/132 >70< Death (%) MACEs (%) Outcomes according to STR, postprocedural MBG and TIMI flow grade Resolution of ST-Segment Elevation (%) Myocardial Blush Grade Postprocedural TIMI flow grade 320/132 >70< P=0.02 P<0.001 P=0.01 P<0.001

POST Samsung Medical Center  The sample size was inadequate to make definite conclusion on clinical outcomes.  This study was not a double-blinded study.  Postconditioning was not performed per protocol (4 cycles of ballooning) in about 8% of patients in the postconditioning group.  ECGs before and 30 minutes after the procedure were not available in 3.5% of all patients.  We excluded patients with hemodynamic instability, cardiogenic shock, or left main lesion who might have lethal reperfusion injury and receive potential benefits from postconditioning. Study Limitations

POST Samsung Medical Center In this multicenter, prospective, randomized, open-label, blinded endpoint trial,  Ischemic postconditioning with primary PCI did not improve myocardial reperfusion compared with conventional primary PCI.  Clinical outcomes at 1-month were not significantly different between the randomized groups.  Cardioprotective effect of ischemic postconditioning was not found in any of prespecified subgroups. Conclusions